Skip to main content
Clinical Trials/JPRN-jRCTs031230358
JPRN-jRCTs031230358
Recruiting
N/A

Exploratory study for the usefulness of early introduction of anifrolumab in the first remission induction therapy for systemic lupus erythematosus

Tsuboi Hiroto0 sites10 target enrollmentSeptember 22, 2023

Overview

Phase
N/A
Intervention
Not specified
Conditions
systemic lupus erythematosus
Sponsor
Tsuboi Hiroto
Enrollment
10
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 22, 2023
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Tsuboi Hiroto

Eligibility Criteria

Inclusion Criteria

  • 1\) Diagnosed with SLE based on either the 2019 EULAR/ACR classification criteria or the 1997 ACR classification criteria
  • 2\) No history of systemic administration of immunosuppressive or immunomodulatory drugs for SLE and within six months of diagnosis
  • 3\) SLEDAI\-2K score of 4 or higher, indicating active disease
  • 4\) Age 18 years or older and younger than 80 years at the time of obtaining consent
  • 5\) Patients who have provided written consent for study participation after receiving a full explanation and understanding

Exclusion Criteria

  • 1\) Steroid therapy exceeding a prednisolone equivalent dose of 0\.6mg/kg/day as initial treatment
  • 2\) Carriers of hepatitis viruses or have active HBV/HCV infections
  • 3\) History of HBV/HCV infection (excluding cases with negative nucleic acid quantification tests)
  • 4\) Severe liver disease (AST or ALT \>\=100 U/L)
  • 5\) Severe kidney disease (serum creatinine \>\=2mg/dL)
  • 6\) Active tuberculosis infection
  • 7\) Current or history of malignant tumors (excluding cases with no recurrence for more than 5 years, and cervical cancer treated with only with local therapy that remaining in situ and no metastasis for more than 3 years)
  • 8\) Suspected active infection
  • 9\) Pregnant or may be pregnant female
  • 10\) Lactating female

Outcomes

Primary Outcomes

Not specified

Similar Trials